Allergy Asthma Immunol Res.  2009 Oct;1(1):3-9. 10.4168/aair.2009.1.1.3.

Allergen-induced airway inflammation and its therapeutic intervention

• O'Byrne PM

• KMID: 2133793
• DOI: http://doi.org/10.4168/aair.2009.1.1.3

Abstract

Allergen inhalation challenge has been useful for examining the mechanisms of allergen-induced airway inflammation and the associated physiological changes and for documenting the efficacy of drugs to treat asthma. Allergen inhalation by a sensitized subject results in acute bronchoconstriction, beginning within 15-30 min and lasting 1-3 hr, which can be followed by the development of a late asthmatic response. Individuals who develop both an early and late response after allergen have more marked increases in airway hyperresponsiveness, and greater increases in allergen-induced airway inflammation, particularly in airway eosinophils and basophils. All of the currently available and effective treatments for asthma modify some aspects of allergen-induced responses. These medications include short-acting and long-acting inhaled beta2-agonists, inhaled corticosteroids, cromones, methylxanthines, leukotriene inhibitors, and anti-IgE monoclonal antibody. In addition, allergen inhalation challenge has become a useful method which can, in a very limited number of patients, provide key information on the therapeutic potential of new drugs being developed to treat asthma.

Keyword

asthma; allergen; inflammation; drug development

MeSH Terms

Adrenal Cortex Hormones
Antibodies, Anti-Idiotypic
Asthma
Basophils
Bronchoconstriction
Eosinophils
Humans
Inflammation
Inhalation
Adrenal Cortex Hormones
Antibodies, Anti-Idiotypic

Figure

• 

  Fig. 1 The effect of therapy on the airway response to inhaled allergen; demonstrating time course of the mean (SD) decline in FEV1 (expressed as percent of pre-challenge FEV1 values) following allergen challenge to assess the efficacy of ten days of treatment with an inhaled corticosteroid (budesonide; 400 mcg daily) and a leukotriene antagonist (montelukast; 10 mg daily) on the early and late airway response to inhaled allergen in ten asthmatic subjects. Significant attenuation of the early response was observed with either montelukast or the combination of budesonide and montelukast when compared with placebo. Significant attenuation of the late airway response was observed by all three active treatment regimens when compared with placebo.49

• 

  Fig. 2 The mean (SD) percentage of sputum eosinophils before and after an inhaled corticosteroid (budesonide) and a leukotriene antagonist (montelukast) before and following an allergen inhalation challenge. There was a subsequent reduction in the allergen-induced eosinophilia in the presence of all treatments. *Indicates significant difference from pre-allergen value in the same treatment group. Filled triangles indicate a significant difference from placebo at the same time point.49

Reference

1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008. 31:143–178.

2. Kirby JG, Hargreave FE, Gleich GJ, O'Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis. 1987. 136:379–383.

3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004. 170:836–844.

4. Blackley CH. Experimental researches on the cause and nature of Catarrhus aestivus (Hay-fever or Hay-asthma). 1873. London: Balliere Tindall & Cox.

5. Herxheimer H. The late bronchial reaction in induced asthma. Int Arch Allergy Appl Immunol. 1952. 3:323–328.

6. O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis. 1987. 136:740–751.

7. Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy. 1977. 7:503–513.

8. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol. 1982. 70:170–177.

9. De Monchy JG, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985. 131:373–376.

10. Gauvreau GM, Lee JM, Watson RM, Irani AM, Schwartz LB, O'Byrne PM. Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. Am J Respir Crit Care Med. 2000. 161:1473–1478.

11. Wood-Baker R, Finnerty JP, Holgate ST. Plasma and urinary histamine in allergen-induced early and late phase asthmatic responses. Eur Respir J. 1993. 6:1138–1144.

12. Manning PJ, Rokach J, Malo JL, Ethier D, Cartier A, Girard Y, Charleson S, O'Byrne PM. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990. 86:211–220.

13. Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O'Byrne PM, Deschesnes F, Boulet LP, Cockcroft DW. Single dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009. 33:1302–1308.

14. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993. 342:833–837.

15. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol. 1995. 96:44–49.

16. Gauvreau GM, Jordana M, Watson RM, Cockroft DW, O'Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997. 156:1738–1745.

17. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet. 1990. 336:1338–1342.

18. Dente FL, Bancalari L, Bacci E, Bartoli ML, Carnevali S, Cianchetti S, Di Franco A, Giannini D, Vagaggini B, Testi R, Paggiaro PL. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. Thorax. 1999. 54:622–624.

19. Wong BJ, Dolovich J, Ramsdale EH, O'Byrne P, Gontovnick L, Denburg JA, Hargreave FE. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am Rev Respir Dis. 1992. 146:1156–1160.

20. Pedersen B, Dahl R, Larsen BB, Venge P. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy. 1993. 48:377–382.

21. Weersink EJ, Aalbers R, Koeter GH, Kauffman HF, De Monchy JG, Postma DS. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol. Am J Respir Crit Care Med. 1994. 150:1262–1267.

22. Pizzichini MM, Kidney JC, Wong BJ, Morris MM, Efthimiadis A, Dolovich J, Hargreave FE. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Eur Respir J. 1996. 9:449–455.

23. Brusasco V, Crimi E, Gherson G, Nardelli R, Oldani V, Francucci B, Della Cioppa G, Senn S, Fabbri LM. Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction. Pulm Pharmacol Ther. 2002. 15:399–406.

24. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med. 2001. 163:881–886.

25. Dente FL, Bacci E, Bartoli ML, Cianchetti S, Di Franco A, Giannini D, Taccola M, Vagaggini B, Paggiaro PL. One week treatment with salmeterol does not prevent early and late asthmatic responses and sputum eosinophilia induced by allergen challenge in asthmatics. Pulm Pharmacol Ther. 2004. 17:147–153.

26. Pauwels R, Van RD, Van der SM, Johannesson N, Persson CG. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol. 1985. 76:583–590.

27. Crescioli S, Spinazzi A, Plebani M, Pozzani M, Mapp CE, Boschetto P, Fabbri LM. Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects. Ann Allergy. 1991. 66:245–251.

28. Hendeles L, Harman E, Huang D, O'Brien R, Blake K, Delafuente J. Theophylline attenuation of airway responses to allergen: comparison with cromolyn metered-dose inhaler. J Allergy Clin Immunol. 1995. 95:505–514.

29. Kraft M, Pak J, Borish L, Martin RJ. Theophylline's effect on neutrophil function and the late asthmatic response. J Allergy Clin Immunol. 1996. 98:251–257.

30. Cockcroft DW, Murdock KY, Gore BP, O'Byrne PM, Manning P. Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine. J Allergy Clin Immunol. 1989. 83:913–920.

31. Jaffar ZH, Sullivan P, Page C, Costello J. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J. 1996. 9:456–462.

32. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998. 157:S1–S53.

33. Cockcroft DW, McParland CP, O'Byrne PM, Manning P, Friend JL, Rutherford BC, Swystun VA. Beclomethasone given after the early asthmatic response inhibits the late response and the increased methacholine responsiveness and cromolyn does not. J Allergy Clin Immunol. 1993. 91:1163–1168.

34. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses,late asthmatic responses,and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987. 79:734–740.

35. Pepys J, Davies RJ, Breslin AB, Hendrick DJ, Hutchcroft BJ. The effects of inhaled beclomethasone dipropionate (Becotide) and sodium cromoglycate on asthmatic reactions to provocation tests. Clin Allergy. 1974. 4:13–24.

36. Kidney JC, Boulet LP, Hargreave FE, Deschesnes F, Swystun VA, OByrne PM, Choudry N, Morris MM, Jennings B, Andersson N, Andreasson A, Cockcroft DW. Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge model. J Allergy Clin Immunol. 1997. 100:65–70.

37. Pepys J. Gell PGH, Coombs RRA, Lachman PJ, editors. Atopy. Clinical aspects of immunology. 1975. Oxford: Blackwell Scientific Publications;877–902.

38. Burge PS, Efthimiou J, Turner-Warwick M, Nelmes PT. Double-blind trials of inhaled beclomethasone diproprionate and fluocortin butyl ester in allergen-induced immediate and late asthmatic reactions. Clin Allergy. 1982. 12:523–531.

39. De Baets FM, Goeteyn M, Kerrebijn KF. The effect of two months of treatment with inhaled budesonide on bronchial responsiveness to histamine and house-dust mite antigen in asthmatic children. Am Rev Respir Dis. 1990. 142:581–586.

40. Swystun VA, Bhagat R, Kalra S, Jennings B, Cockcroft DW. Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol. 1998. 102:363–367.

41. Wong CS, Wahedna I, Pavord ID, Tattersfield AE. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Respir Crit Care Med. 1994. 150:1268–1273.

42. Booij-Noord H, Orie NG, De VK. Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone. J Allergy Clin Immunol. 1971. 48:344–354.

43. Pepys J, Hargreave FE, Chan M, McCarthy DS. Inhibitory effects of disodium cromoglycate on allergen-inhalation tests. Lancet. 1968. 2:134–137.

44. Dahl R, Pedersen B. Influence of nedocromil sodium on the dual asthmatic reaction after allergen challenge: a double-blind, placebo-controlled study. Eur J Respir Dis. 1986. 69:263–265.

45. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991. 337:690–694.

46. Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J. 1994. 7:324–331.

47. Hamilton A, Faiferman I, Stober P, Watson RM, O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol. 1998. 102:177–183.

48. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA, Seidenberg BC, Zwinderman AH, Peszek I, Sterk PJ. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy. 1999. 29:42–51.

49. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, O'Byrne PM. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002. 166:1212–1217.

50. Palmqvist M, Bruce C, Sjostrand M, Arvidsson P, Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy. 2005. 60:65–70.

51. Nakazawa T, Toyoda T, Furukawa M, Taya T, Kobayashi S. Inhibitory effects of various drugs on dual asthmatic responses in wheat flour-sensitive subjects. J Allergy Clin Immunol. 1976. 58:1–9.

52. Adachi M, Kobayashi H, Aoki N, Iijima M, Kokubu F, Furuya A, Takahashi T. A comparison of the inhibitory effects of ketotifen and disodium cromoglycate on bronchial responses to house dust, with special reference to the late asthmatic response. Pharmatherapeutica. 1984. 4:36–42.

53. Rafferty P, Ng WH, Phillips G, Clough J, Church MK, Aurich R, Ollier S, Holgate ST. The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma. J Allergy Clin Immunol. 1989. 84:649–657.

54. Hamid M, Rafferty P, Holgate ST. The inhibitory effect of terfenadine and flurbiprofen on early and late-phase bronchoconstriction following allergen challenge in atopic asthma. Clin Exp Allergy. 1990. 20:261–267.

55. Cockcroft DW, Keshmiri M, Murdock KY, Gore BC. Allergen-induced increase in airway responsiveness is not inhibited by acute treatment with ketotifen or clemastine. Ann Allergy. 1992. 68:245–250.

56. Twentyman OP, Ollier S, Holgate ST. The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma. J Allergy Clin Immunol. 1993. 91:1169–1178.

57. Wasserfallen JB, Leuenberger P, Pecoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol. 1993. 91:1189–1197.

58. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB Jr, Cockcroft DW. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997. 155:1835–1840.

59. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997. 155:1828–1834.

60. Freitag A, Watson RM, Matsos G, Eastwood C, O'Byrne PM. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. Thorax. 1993. 48:594–598.

61. Evans DJ, Barnes PJ, Cluzel M, O'Connor BJ. Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Respir Crit Care Med. 1997. 156:11–16.

62. Manning PJ, Stevens WH, Cockcroft DW, O'Byrne PM. The role of thromboxane in allergen-induced asthmatic responses. Eur Respir J. 1991. 4:667–672.

63. Beasley RC, Featherstone RL, Church MK, Rafferty P, Varley JG, Harris A, Robinson C, Holgate ST. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol. 1989. 66:1685–1693.

64. Norris V, Choong L, Tran D, Corden Z, Boyce M, Arshad H, Holgate S, O'Connor B, Millet S, Miller B, Rohatagi S, Kirkesseli S. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol. 2005. 116:761–767.

65. O'Shaughnessy KM, Taylor IK, O'Connor B, O'Connell F, Thomson H, Dollery CT. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis. 1993. 147:1431–1435.

66. Barnes PJ. New therapies for asthma. Trends Mol Med. 2006. 12:515–520.

67. Nagai H, Teramachi H, Tuchiya T. Recent advances in the development of anti-allergic drugs. Allergol Int. 2006. 55:35–42.

68. Holt PG. Key factors in the development of asthma: atopy. Am J Respir Crit Care Med. 2000. 161:S172–S175.

69. Kips JC, Inman MD, Jayaram L, Bel EH, Parameswaran K, Pizzichini MM, Pavord ID, Djukanovic R, Hargreave FE, Sterk PJ. The use of induced sputum in clinical trials. Eur Respir J Suppl. 2002. 37:47s–50s.

70. Kharitonov SA, Barnes PJ. Exhaled biomarkers. Chest. 2006. 130:1541–1546.